PARP1 and cancer: A meta-analysis compared the safety and tolerability of approved PARP inhibitors (fluzoparib, olaparib, rucaparib, niraparib, or talazoparib) in 10 head-to-head phase II and phase III randomized controlled trials (RCTs), with either placebo or chemotherapy, in cancer patients [72].